

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Modern Chinese Medicine Group Co., Ltd.

現代中藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1643)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2024 ANNUAL REPORT

Reference is made to the annual report of Modern Chinese Medicine Group Co., Ltd. (the “**Company**”) for the financial year ended 31 December 2024 (“**2024 Annual Report**”). Unless otherwise provided, capitalised terms used in this announcement shall have the same meanings as those used in the 2024 Annual Report.

The Company would like to provide the following details of the Scheme:

The total number of Shares available for issue under the Scheme is 60,000,000 Shares, representing 10% of the then entire issued share capital of the Company as at the date of the 2024 Annual Report.

Pursuant to the Scheme, the period within which a grantee may exercise of the option pursuant to the terms and conditions of the Scheme to be notified by the Board to each grantee which the Board may in its absolute discretion determine, save that such period shall not be more than ten (10) years from the commencement date in respect of any particular option.

As the Scheme was effective on 15 January 2021, a date prior to the effective date of the new requirements under Chapter 17 of the Listing Rules, nothing in the terms of the Scheme has mentioned about a stipulated vesting period. Nonetheless, the Board may, on a case-by-case basis and at its discretion when making an offer, impose a vesting period.

As disclosed on page 58 of the 2024 Annual Report, the maximum number of Shares which may be issued upon exercise of all options to be granted under the Scheme and other schemes shall not, in aggregate, exceed 10% of the Shares in issue as at the listing date of the Shares. As no option has been granted by the Company under the Scheme since its inception, the number of options available for grant under the Scheme Mandate Limit at the beginning and the end of the Year 2024 is 60,000,000 (i.e. 60,000,000 Shares may be issued under the Scheme).

By Order of the Board
Modern Chinese Medicine Group Co., Ltd.
Zhang Hongli
Executive Director

Hong Kong, 18 December 2025

As at the date of this announcement, the Board comprises three executive Directors, namely Ms. Sun Xinlei, Ms. Zhang Hongli and Ms. Jia Yanru; and three independent non-executive Directors, namely Ms. Liu Ling, Mr. Leung Tsz Wing and Mr. Wong Chi Kin.